Since the CAF-S1 and pCAF subsets characterize HER2+ BC unresponsive to trastuzumab (Fig. 1d, e), we conducted a detailed analysis of FAP expression pattern in HER2+ BC. Here, ERBB2 is linked to breast cancer.